Subjects will be divided into two cohorts, with each cohort consisting of three to six individuals. Credit: Volha_R/Shutterstock. Verismo Therapeutics has commenced the first patient dosing in its ...

Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed at the Sarah Cannon Research Institute of Colorado ...

University of Pennsylvania spinout Verismo Therapeutics is being acquired by South Korea-based HLB Group, which already owns an almost 50 percent stake in the firm, writes John George for the ...

The cost for the United Kingdom's Electronic Travel Authorization approval could increase to £16 from £10, according to changes proposed Thursday by the U.K. government. The new ETA requirement just ...

If you’re looking to make your own drinks at home, one of the best espresso machines can help you turn your kitchen into your own personal coffee shop. Our favorite pick overall in 2025 ...

Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of ...

10, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has dosed the first patient in its CELESTIAL-301 ...